US Trastuzumab Competition Heats Up

Mylan And Biocon’s Ogivri Biosimilar Leads New Wave Of Herceptin Rivals

 
• By Dave Wallace

Mylan and Biocon have launched their Ogivri trastuzumab biosimilar in the US, marking the second biosimilar rival to Herceptin and leading a new wave of trastuzumab biosimilars expected to arrive in the US early next year.

Horse racing
Mylan and Biocon follow Amgen into the biosimilar trastuzumab market, with other firms close behind • Source: Shutterstock

More from Biosimilars

More from Products